Veru preparing for launch as it submits sabizabulin EUA

Florida, USA-based Veru (Nasdaq: VERU), a biopharma developing novel medicines for COVID-19 and other viral and acute respiratory distress syndrome (ARDS)-related diseases and for the management of breast and prostate cancers, was trading 15% higher an hour after New York trading began on Tuesday.

The US company announced that it has submitted an emergency use authorization (EUA) application to the US Food and Drug Administration (FDA) for its sabizabulin oral 9mg treatment of moderate to severe hospitalized COVID-19 patients at high risk for developing (ARDS).

Veru announced stellar Phase III data on sabizabulin in this indication in April, and the company has since received encouraging signs from the FDA that those results would be enough to support an EUA application.